Cardiopulmonary Exercise Testing to Evaluate Pulmonary AVMs

Not Applicable

Completed

• Conditions: Pulmonary Arteriovenous Malformations; Hereditary Hemorrhagic Telangiectasia
• Interventions: Other: Cardiopulmonary exercise test; Procedure: Blood test

• Registration Number: NCT02436213
• Lead Sponsor: Imperial College London

Brief Summary

Pulmonary arteriovenous malformations (PAVMs) are a rare vascular condition affecting the lungs. PAVMs lead to low blood oxygen levels, yet are very well tolerated by patients. This study will examine the exercise capacity of PAVM patients using formal cardiopulmonary exercise tests performed on a stationary bicycle.

Detailed Description

It is well known that the lung is the site at which oxygen enters the blood stream, diffusing from the alveolar air sacs into the pulmonary capillaries. This newly oxygenated blood is carried to the heart in the pulmonary veins, then passes into the systemic circulation to provide oxygen to the tissues.

Patients with pulmonary arteriovenous malformations (PAVMs) have abnormal vascular connections between pulmonary arteries and pulmonary veins in the lung. Blood flowing through PAVMs therefore bypasses the oxygenation sites in the pulmonary capillaries. Low blood oxygen levels (hypoxemia) is frequent in PAVM patients but breathlessness (dyspnea) is not. The investigators have shown that dyspnea was not a common presenting complaint in a large UK series, and that there is little correlation between severity of dyspnea in PAVM patients, and blood oxygen levels.

In this study the investigators will address the question "Why are hypoxemic PAVM patients not more dyspneic?"

The investigators will address this by first performing standardised cardiopulmonary exercise testing, as used in the clinic, on age and sex matched patients with PAVMs and healthy controls. Physiological parameters will be compared, to test the null hypothesis that the impact of exercise on PAVM patients' cardiopulmonary systems does not differ to normal controls.

If the expected differences are confirmed, the investigators will examine if there is any difference to normals by re-examining the exercise tolerance of the PAVM cohort after they have had their PAVMs treated by embolization.

Most patients with PAVMs have an underlying hereditary vascular disorder, hereditary haemorrhagic telangiectasia. Assuming the expected differences between PAVM patients and controls are confirmed, the investigators will therefore also examine which pattern HHT patients without PAVMs display. Finally, cellular and molecular methods will be used to dissect mechanistic pathways.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2011-04
• Study First Submitted: 2012-10-16
• Primary Completion: 2015-03
• Study Completion: 2015-03
• Study First Submitted QC: 2015-05-01
• Study First Posted: 2015-05-06
• Status Verified: 2023-09
• Last Update Submitted: 2023-09-25
• Last Update Posted: 2023-09-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 39

Inclusion Criteria

• Ability to provide informed consent
• Healthy volunteers: no concurrent health reason to avoid exercise
• Pulmonary AVMs: pulmonary AVMs confirmed by CT scan
• Hereditary hemorrhagic telangiectasia without pulmonary AVMs: HHT according to current international consensus criteria, with no evidence of PAVMs on dedicated thoracic CT scan.

Read More

Exclusion Criteria

• Inability to provide informed consent.
• Any known cardiovascular abnormality including a history of syncope (faintness, dizziness, lightheadedness or loss of consciousness due to an abnormality of the cardiovascular system).
• Current respiratory tract infection (eg a cold).
• Pregnancy.
• Claustrophobia or needle phobia

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Healthy control	Blood test	A group of up to 30 healthy controls will be recruited to have a cardiopulmonary exercise test and a blood test.
HHT but no pulmonary AVM	Cardiopulmonary exercise test	Most patients with pulmonary AVMs have underlying hereditary hemorrhagic telangiectasia (HHT). If there is a difference between pulmonary AVM and control groups that does not correct following embolization of pulmonary AVMs, a group of up to 30 people with HHT but no evidence of pulmonary AVMs will be selected to have a cardiopulmonary exercise test and a blood test.
HHT but no pulmonary AVM	Blood test	Most patients with pulmonary AVMs have underlying hereditary hemorrhagic telangiectasia (HHT). If there is a difference between pulmonary AVM and control groups that does not correct following embolization of pulmonary AVMs, a group of up to 30 people with HHT but no evidence of pulmonary AVMs will be selected to have a cardiopulmonary exercise test and a blood test.
Healthy control	Cardiopulmonary exercise test	A group of up to 30 healthy controls will be recruited to have a cardiopulmonary exercise test and a blood test.
Pulmonary AVM	Cardiopulmonary exercise test	A group of up to 30 pulmonary AVM patients will be recruited to have a cardiopulmonary exercise test, and a blood test.
Pulmonary AVM	Blood test	A group of up to 30 pulmonary AVM patients will be recruited to have a cardiopulmonary exercise test, and a blood test.

Primary Outcome Measures

Name	Time	Method
Total body oxygen consumption in mls/min/kg, at peak exercise (VO2 max).	Same day (Day 1), at end of exercise study	Of the many measurements and derived indices that can be measured during cardiopulmonary exercise testing, the peak consumption of oxygen (VO2 max) is perhaps the best indicator of integrated cardiorespiratory capacity. The principle research question will therefore test the null hypothesis that "The VO2 max does not differ between PAVM patients and age matched healthy controls."

Secondary Outcome Measures

Name	Time	Method
Breathing reserve (%)	Same day (Day 1) at end of exercise test	We will also test in univariate and multiple regression analyses whether breathing reserve differs between PAVM patients and controls.
Ventilatory efficiency, derived from the VE / CO2 slope (L/min/L/min)	Same day (Day 1), at end of exercise study	We will also test in univariate and multiple regression analyses whether ventilatory efficiency differs between PAVM patients and controls.

Trial Locations

Locations (1)

Hammersmith Hospital, Du Cane Rd; 🇬🇧 London, United Kingdom